Your current location: Home·News

Latest news



You Jianfeng went to Yuexi Subdistrict to conduct a "Thousands of Villages, Thousands of Enterprises, Thousands of Households" visit

In accordance with the thematic education deployment requirements of the Party Central Committee and the Provincial Party Committee and the work arrangements of the Municipal Party Committee, today (November 23), You Jianfeng, member of the Standing Committee of the District Party Committee, Director of the Propaganda Department, and Director of the United Front Work Department, launched the "Thousands of Villages, Thousands of Enterprises, Thousands of Homes" campaign in Yuexi Subdistrict. Visit every household, go deep into the grassroots, into enterprises, and into the masses, strengthen services, promote development, observe people's conditions, and resolve people's concerns. He emphasized that we must adhere to the guidance of Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, proactively connect with enterprises, ask for their needs and serve them, and use practical measures to help enterprises solve practical difficulties and continuously enhance their sense of gain and satisfaction.

Suzhou Xishan Zhongke Pharmaceutical Research and Development Co., Ltd.

The company is committed to providing global customers with a full range of high-tech research services on safety evaluation, ecotoxicology testing, pharmacodynamics and pharmacokinetics of drugs, pesticides and chemicals. Organization for GLP testing of chemicals. It undertakes the research tasks of the Suzhou Biomedical Service Platform Construction Project and the Suzhou Science and Technology Plan Key Industrial Technology Innovation Project. It is a high-tech enterprise in Jiangsu Province, a R&D enterprise in Jiangsu Province, and the Jiangsu Province Pesticide Toxicology Evaluation and Risk Assessment Engineering Technology Research Center.

WeChat screenshot_20240117213909.png

You Jianfeng walked into the laboratory and workshop, communicated cordially with scientific researchers and staff, and gained an in-depth understanding of the company's main projects and specific research and development processes. Focusing on the development prospects of the company, You Jianfeng said that the company must strengthen confidence, be determined to innovate, further strengthen research in areas of expertise, continue to promote technological progress, and promote the company to become stronger and better with higher product quality and better services. .



Suzhou Xishan Zhongke passed the clinical testing indicator proficiency verification activity of China Institute for Food and Drug Control with full scores for four consecutive years

Recently, the China Institute of Food and Drug Control has successively released proficiency verification reports for various clinical testing indicators in 2022. Suzhou Xishan Zhongke Clinical Laboratory has participated in a total of 37 tests in the four major categories of hematology, hemagglutination, urine biochemistry and serum biochemistry. Satisfactory results were obtained in the proficiency testing activities for each testing indicator. This is the fourth consecutive year that Suzhou Xishan Zhongke Clinical Laboratory has obtained the same perfect score since it began to participate in this proficiency testing activity in 2019. This fully demonstrates that the testing capabilities of Suzhou Xishan Zhongke Clinical Laboratory are leading the domestic industry. level, all test results are accurate and reliable.




The Pathology Department participated in the "Inter-Laboratory Comparison of Toxicity Pathology Detection" activity and won great results!

In order to further improve the toxic pathology testing service level of Suzhou Xishan Zhongke, a total of 7 diagnostic staff from the Pathology Department, Chen Wei, Gong Ting, Zhang Qiongfang, Gao Feilong, Tan Ting, Gu Yuting and Guo Qian, participated in the 2022 Toxicity Pathology Testing Laboratory Inter-Laboratory Comparison. The pathological diagnosis project was assessed and won good results in this comparison.

The event was jointly organized by the Toxic Pathology Professional Committee of the Chinese Society of Toxicology and the Guangdong Provincial Institute of Occupational Disease Prevention and Control, and invited major universities, scientific research institutions, testing institutions, etc. across the country to participate in the evaluation. The experimental samples assessed in the pathological diagnosis project are SD rats, ICR mice, rasH2 mice and cynomolgus monkeys, involving parathyroid gland, kidney, retina, liver, Harderian gland, ovary, heart, pituitary gland tumors and non-tumor lesions 8 cases in total.

The Pathology Department of Suzhou Xishan Zhongke University of Science and Technology received an assessment certificate with an "excellent" comparison result, which further proves that our pathological diagnostic staff have high diagnostic level and ability, ensuring the reliability and high quality of drug toxicity evaluation services.



Xishan passed (NMPA) GLP certification

On August 29, 2022, the National Medical Products Administration (NMPA) organized an expert group to conduct regular laboratory GLP certification inspections on Suzhou Xishan Zhongke Pharmaceutical Research and Development Co., Ltd. Recently, the company received an inspection result notice from the Drug Registration Department of the State Food and Drug Administration: The unit basically complies with GLP requirements in terms of organization, management and personnel, instruments, equipment and experimental materials, standard operating procedures and test operations for drug safety evaluation, and is carcinogenic. Tests, single and multiple dose toxicity tests (rodents), single and multiple dose toxicity tests (non-rodents), toxicokinetic tests, immunogenicity tests, safety pharmacology tests, local toxicity tests , Reproductive toxicity test (section I, II, III), genotoxicity test (Ames, micronucleus, chromosomal aberration, mouse lymphoma test) items comply with GLP regular inspection requirements. In the future, Suzhou Xishan Zhongke will stick to its original intention and move forward firmly, provide good drug registration, pharmacology and toxicology CRO technical services, and add support to the innovation and development of medicine!

WeChat screenshot_20240117213612.png



Xishan Zhongke adds pesticide GLP test scope

On February 22, 2021, the official website of the Ministry of Agriculture and Rural Affairs of the People's Republic of China issued an announcement announcing the approval of 8 units including Suzhou Xishan Zhongke Pharmaceutical Research and Development Co., Ltd. as pesticide registration test units.

On the basis of the original, Xishan Zhongke has newly added test scopes including - residue test: metabolism test (animal metabolism, plant metabolism), environmental impact test: ecotoxicology test Category B (B1, B2, B5, B6) environmental classification Trend test categories A and B.

Our company will, as always, provide pesticide registration and testing services to ensure the scientificity, accuracy and standardization of testing!

WeChat screenshot_20240117213337.png

WeChat screenshot_20240117213344.png



Suzhou Xishan Xike was commended again by: notification!

The 2020 Wuzhong District Comprehensive Commendation List was announced at the meeting. Xishan Zhongke won three honorary titles: "High-Growth Technology Enterprise", "Advanced Enterprise in Manufacturing Transformation and Upgrading—Industrial Leading Benchmark Enterprise" and "Excellent Productive Service Enterprise" .

WeChat screenshot_20240117213006.png

WeChat screenshot_20240117213017.png

WeChat screenshot_20240117213025.png



Congratulations to our company for achieving excellent results in the "Inter-laboratory Comparison of Toxic Pathology Testing Laboratories" assessment!

In 2020, Xishan Zhongke selected professional toxicology technicians to participate in the Chemical Toxicity Evaluation Center of the Guangdong Provincial Institute for Occupational Disease Prevention and Control (Guangdong Provincial Occupational Health Testing Center) jointly sponsored by the Toxic Pathology Professional Committee of the Chinese Society of Toxicology and the Guangdong Provincial Institute for Occupational Disease Prevention and Control. Organized and implemented the 2020 inter-laboratory comparison activity for toxicological pathology testing.

In this event, a total of 96 units participated in the inter-laboratory comparison assessment, including R&D units, universities, and testing institutions in various provinces and cities. Recently, our company received an assessment certificate from the comparison activity, and the evaluation result was "excellent", which fully demonstrates that our company's toxicological pathology testing level is at the leading level in the domestic industry, and the test results are accurate and authoritative.

This evaluation has strengthened exchanges among peers in toxicological pathology testing and is of great significance to promoting the standardization and high-quality development of pathological diagnosis in my country.

WeChat screenshot_20240117212830.png



The Jiangsu Provincial Red Cross Society awarded Xishan Zhongke the "Fraternity Award"

On December 23, 2020, Xishan Zhongke Company was invited to participate in the non-invasive ventilator and AED machine donation ceremony and caring enterprise representative symposium held by the Jiangsu Provincial Red Cross Society in Nanjing.

WeChat screenshot_20240117212553.png

At the meeting, the Provincial Red Cross Society commended the companies that made outstanding contributions during the epidemic, and awarded Suzhou Xishan Zhongke Pharmaceutical Research and Development Co., Ltd. the "Jiangsu Provincial Red Cross Fraternity Award" to thank the companies for their support for the development of the Red Cross and their efforts in positive response in the fight against the epidemic. As a socially responsible enterprise, after the outbreak of the new coronavirus infection pneumonia, Xishan Zhongke quickly donated 1 million yuan through the Red Cross Society of Wuzhong District, Suzhou City to support nationwide epidemic prevention and control work.

WeChat screenshot_20240117212622.png

"Humanity, fraternity, and dedication" is a long-term path. Xishan Zhongke will adhere to the concept of "taking from the society and giving back to the society" and actively participate in public welfare undertakings to help the Red Cross flourish.

WeChat screenshot_20240117212639.png



Wuzhong District leaders visited our company to investigate the development of the biopharmaceutical industry

 On the afternoon of May 6 (Wednesday), district leaders Li Chaoyang and Zhang Huaqian led a team including the district government office, National Development and Reform Commission, Industry and Information Technology Bureau, Science and Technology Bureau, Market Supervision Bureau, Emergency Management Bureau and the main leaders of the development zone to Xishan Central Scientific research on the development of biomedicine.

    Song Hongyu, chairman of the company, and Zheng Xia, head of the organization, led a tour of the laboratory and introduced in detail the current technological development and operations. District Mayor Li and his party listened to the report of Xishan Zhongke in detail and said that the development of the biopharmaceutical industry is the general trend at present. Enterprises must seize the opportunity to provide higher-quality public technical services to the majority of pharmaceutical companies and continuously promote industrial technological progress.

    Xishan Zhongke will uphold the Suzhou spirit of "open innovation", give full play to its supporting role in medical research and development, promote collaborative innovation among medical research enterprises, and continue to add support to the creation of "China's Pharmaceutical Valley"!

WeChat screenshot_20240117212432.png

Copyright 2023 Suzhou Xishan Zhongke Pharmaceutical Research and Development Co., Ltd All Rights Reserved. Privacy clause | Information security | Legal notice